David Bernard Miklos, MD

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

5 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Miklos’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

5 of 5 plans

Sort by

Plans whose provider directory lists this clinician

SCAN Balance (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Classic (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN MyChoice (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Strive (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence G87296 · Current

Licensed to practise in California · since 2004 · expires 2028-02-29 · Yale University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$51,610

Medicare paid this office $51,610 for 104 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	37	$26,768	$106
Long return visit (40+ min)	51	$12,866	$124
Long return visit (40+ min)	23	$5,622	$165
Hospital discharge day management, more than 30 minutes	14	$1,675	$105

Who their Medicare patients are

104 Original Medicare patients in 2024. Average age 72 · Women 40% · Also on Medicaid 21% · Health risk score 2.67. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 69% · Atrial fibrillation 26% · Coronary heart disease 25% · Chronic kidney disease 24% · Diabetes 18% · Cancer 17% · Depression 17% · Heart failure 15% · Dementia 12% · COPD 11%.

The office billed $185,656, Medicare allowed $65,923 and paid $51,610; for 440 services of 12 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	104	440	72	2.67	$185,656	$51,610
2023	83	287	70	3.02	$104,169	$35,365
2022	94	474	70	2.52	$195,597	$52,802
2021	89	322	70	2.54	$127,343	$37,855
2020	96	432	68	3.44	$205,223	$42,921
2019	98	336	68	3.11	$125,477	$30,678
2018	105	433	65	3.30	$154,541	$37,728
2017	95	358	65	3.27	$139,893	$30,061
2016	63	225	66	3.28	$79,552	$17,278
2015	66	277	65	3.28	$117,586	$23,905
2014	65	328	61	3.10	$122,778	$27,704
2013	77	372	62	2.99	$157,394	$31,690

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 1 service

Sort by

Original Medicare services billed in 2023

Long return visit (40+ min)	74	$25,681	$126

2022: 4 services

Sort by

Original Medicare services billed in 2022

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	28	$22,677	$93
Long return visit (40+ min)	65	$21,571	$126
Initial hospital care with moderate level of medical decision making at least 75 minutes	16	$2,874	$180
New patient visit (60+ min)	14	$2,409	$172

2021: 3 services

Sort by

Original Medicare services billed in 2021

Long return visit (40+ min)	70	$21,912	$124
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	14	$8,305	$95
New patient visit (60+ min)	11	$1,727	$157

2020: 5 services

Sort by

Original Medicare services billed in 2020

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	32	$21,291	$98
Long return visit (40+ min)	42	$9,512	$105
Return visit (30+ min)	35	$3,146	$58
Initial hospital care with moderate level of medical decision making at least 75 minutes	12	$2,506	$193
Hospital discharge day management, more than 30 minutes	16	$1,864	$104

2019: 5 services

Sort by

Original Medicare services billed in 2019

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	24	$12,074	$94
Return visit (30+ min)	61	$7,794	$65
Long return visit (40+ min)	21	$3,029	$101
Initial hospital care with moderate level of medical decision making at least 75 minutes	11	$2,937	$184
New patient visit (60+ min)	12	$1,533	$128

2018: 4 services

Sort by

Original Medicare services billed in 2018

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	37	$15,541	$94
Return visit (30+ min)	66	$12,473	$67
New patient visit (60+ min)	19	$2,825	$149
Hospital discharge day management, more than 30 minutes	16	$1,580	$99

2017: 3 services

Sort by

Original Medicare services billed in 2017

Return visit (30+ min)	64	$11,906	$67
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	20	$9,815	$93
Long return visit (40+ min)	18	$2,092	$100

2016: 3 services

Sort by

Original Medicare services billed in 2016

Return visit (30+ min)	39	$9,794	$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	12	$3,611	$93
Long return visit (40+ min)	11	$1,656	$92

2015: 2 services

Sort by

Original Medicare services billed in 2015

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	17	$12,277	$92
Return visit (30+ min)	42	$6,683	$64

2014: 3 services

Sort by

Original Medicare services billed in 2014

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	20	$11,368	$92
Return visit (30+ min)	45	$10,058	$67
Long return visit (40+ min)	13	$1,776	$99

2013: 6 services

Sort by

Original Medicare services billed in 2013

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	29	$13,930	$90
Return visit (30+ min)	40	$9,043	$65
Initial hospital care with moderate level of medical decision making at least 75 minutes	13	$2,214	$170
Long return visit (40+ min)	12	$1,627	$90
New patient visit (60+ min)	12	$1,622	$135
Hospital discharge day management, more than 30 minutes	15	$1,424	$95

Medicaid work

$6,202 in 2024

Medicaid paid $6,202 for 66 billed services this clinician did in 2024, up to 15 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

Long return visit (40+ min)	66	$6,202

Sort by

Medicaid work by year

2024	66	1	15	$6,202
2023	115	1	15	$6,473
2022	98	1	16	$5,556
2021	43	1	18	$2,236
2020	41	2	15	$1,845
2019	24	1	16	$1,651
2018	38	1	19	$1,991

See the largest Medicaid services in earlier years

2023

Sort by

Largest Medicaid services in 2023

Long return visit (40+ min)	115	$6,473

2022

Sort by

Largest Medicaid services in 2022

Long return visit (40+ min)	98	$5,556

2021

Sort by

Largest Medicaid services in 2021

Long return visit (40+ min)	43	$2,236

2020

Sort by

Largest Medicaid services in 2020

Long return visit (40+ min)	24	$1,077
Return visit (30+ min)	17	$768

2019

Sort by

Largest Medicaid services in 2019

Return visit (30+ min)	24	$1,651

2018

Sort by

Largest Medicaid services in 2018

Return visit (30+ min)	38	$1,991

Drugs they prescribed that Part D paid

$837,982

Pharmacies billed $837,982 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

550 generic and 110 brand-name prescriptions · $837,982 in drug cost · 193 antibiotic prescriptions to 49 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Imbruvica	None	18	$276,727	$15,374
Calquence	None	12	$163,099	$13,592
Gammagard Liquid	Immune globulin	18	$135,898	$7,550
Posaconazole	None	17	$38,027	$2,237
Atovaquone	None	24	$15,893	$662

See all 13 drugs

Sort by

Every Part D drug this clinician prescribed

Imbruvica	None	18	$276,727	$15,374
Calquence	None	12	$163,099	$13,592
Gammagard Liquid	Immune globulin	18	$135,898	$7,550
Posaconazole	None	17	$38,027	$2,237
Atovaquone	None	24	$15,893	$662
Acyclovir	None	143	$2,510	$18
Sulfamethoxazole-Trimethoprim	None	172	$1,610	$9
Levetiracetam	None	11	$505	$46
Ondansetron	None	20	$199	$10
Prednisone	None	15	$191	$13
Allopurinol	None	28	$161	$6
Lorazepam	None	20	$157	$8
Pantoprazole	None	11	$41	$4

Year by year

Sort by

Part D prescribing by year

2024	660	81	None	17%	$837,982
2023	507	68	None	None	$517,783
2022	519	70	0% (0)	None	$806,756
2021	574	80	None	14%	$751,666
2020	521	65	None	13%	$683,510
2019	681	67	None	17%	$849,663
2018	539	44	None	19%	$623,703
2017	394	46	None	19%	$506,379
2016	377	40	None	16%	$371,318
2015	464	35	None	14%	$377,882
2014	505	48	3% (14)	None	$230,262
2013	569	52	None	None	$170,959

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 10 drugs

Sort by

Part D drugs prescribed in 2023

Gammagard Liquid	Immune globulin	21	$164,518	$7,834
Posaconazole	None	29	$91,015	$3,138
Imbruvica	None	12	$86,701	$7,225
Atovaquone	None	25	$17,197	$688
Acyclovir	None	85	$2,009	$24
Sulfamethoxazole-Trimethoprim	None	140	$1,652	$12
Synthroid	None	12	$577	$48
Ondansetron	None	22	$157	$7
Pantoprazole	None	12	$85	$7
Lorazepam	None	15	$67	$4

2022: 12 drugs

Sort by

Part D drugs prescribed in 2022

Calquence	15	$222,088	$14,806
Imbruvica	16	$210,233	$13,140
Posaconazole	26	$69,897	$2,688
Atovaquone	13	$9,159	$705
Acyclovir	111	$3,034	$27
Sulfamethoxazole-Trimethoprim	107	$1,039	$10
Ondansetron	27	$309	$11
Pantoprazole	23	$290	$13
Prednisone	11	$178	$16
Lorazepam	26	$151	$6
Allopurinol	15	$66	$4
Amoxicillin	13	$56	$4

2021: 15 drugs

Sort by

Part D drugs prescribed in 2021

Imbruvica	20	$333,015	$16,651
Posaconazole	47	$145,808	$3,102
Noxafil	12	$78,171	$6,514
Zarxio	13	$71,880	$5,529
Atovaquone	26	$16,925	$651
Acyclovir	99	$3,338	$34
Dexamethasone	23	$1,122	$49
Sulfamethoxazole-Trimethoprim	94	$943	$10
Ondansetron	29	$429	$15
Prednisone	20	$259	$13
Hydrocortisone	13	$178	$14
Lorazepam	25	$162	$6
Pantoprazole	11	$156	$14
Levofloxacin	12	$149	$12
Allopurinol	26	$118	$5

2020: 14 drugs

Sort by

Part D drugs prescribed in 2020

Imbruvica	27	$445,711	$16,508
Posaconazole	21	$74,252	$3,536
Noxafil	12	$55,687	$4,641
Acyclovir	103	$5,134	$50
Tacrolimus	14	$2,954	$211
Sulfamethoxazole-Trimethoprim	79	$1,001	$13
Fluconazole	13	$776	$60
Dexamethasone	11	$689	$63
Ondansetron	20	$350	$17
Levofloxacin	13	$231	$18
Pantoprazole	19	$197	$10
Amlodipine Besylate	14	$158	$11
Lorazepam	16	$111	$7
Prednisone	20	$92	$5

2019: 20 drugs

Sort by

Part D drugs prescribed in 2019

Imbruvica	None	33	$436,385	$13,224
Noxafil	None	33	$209,097	$6,336
Gamunex-C	Immune globulin	17	$78,424	$4,613
Zarxio	None	11	$56,204	$5,109
Acyclovir	None	102	$2,755	$27
Entecavir	None	16	$2,645	$165
Fluconazole	None	20	$1,647	$82
Tacrolimus	None	11	$1,234	$112
Sulfamethoxazole-Trimethoprim	None	103	$834	$8
Ondansetron	None	22	$347	$16
Prochlorperazine Maleate	None	20	$268	$13
Pantoprazole	None	21	$256	$12
Allopurinol	None	22	$249	$11
Prednisone	None	22	$236	$11
Levofloxacin	None	13	$225	$17
Omeprazole	None	12	$166	$14
Ranitidine	None	14	$161	$12
Lorazepam	None	21	$123	$6
Amlodipine Besylate	None	12	$118	$10
Famotidine	None	11	$108	$10

2018: 15 drugs

Sort by

Part D drugs prescribed in 2018

Imbruvica	None	38	$419,140	$11,030
Noxafil	None	11	$70,193	$6,381
Gamunex-C	Immune globulin	12	$51,318	$4,276
Enoxaparin	None	11	$18,939	$1,722
Acyclovir	None	118	$2,608	$22
Gabapentin	None	14	$1,032	$74
Dexamethasone	None	16	$761	$48
Pantoprazole	None	27	$255	$9
Sulfamethoxazole-Trimethoprim	None	35	$212	$6
Amlodipine Besylate	None	13	$163	$13
Ondansetron	None	15	$160	$11
Allopurinol	None	15	$150	$10
Famotidine	None	22	$127	$6
Levothyroxine	None	12	$69	$6
Lorazepam	None	11	$30	$3

2017: 8 drugs

Sort by

Part D drugs prescribed in 2017

Imbruvica	35	$370,231	$10,578
Acyclovir	77	$1,282	$17
Gabapentin	17	$393	$23
Pantoprazole	17	$152	$9
Sulfamethoxazole-Trimethoprim	15	$135	$9
Famotidine	17	$124	$7
Lorazepam	17	$104	$6
Amlodipine Besylate	12	$51	$4

2016: 11 drugs

Sort by

Part D drugs prescribed in 2016

Imbruvica	30	$297,798	$9,927
Enoxaparin	13	$34,894	$2,684
Acyclovir	79	$1,824	$23
Gabapentin	12	$345	$29
Prednisone	15	$235	$16
Famotidine	14	$225	$16
Ciprofloxacin	12	$209	$17
Sulfamethoxazole-Trimethoprim	23	$207	$9
Pantoprazole	14	$120	$9
Lorazepam	12	$84	$7
Azithromycin	12	$78	$6

2015: 8 drugs

Sort by

Part D drugs prescribed in 2015

Imbruvica	31	$293,069	$9,454
Voriconazole	30	$25,993	$866
Enoxaparin	11	$24,980	$2,271
Acyclovir	78	$1,756	$23
Tacrolimus	13	$1,733	$133
Prednisone	37	$447	$12
Sulfamethoxazole-Trimethoprim	49	$347	$7
Pantoprazole	33	$279	$8

2014: 11 drugs

Sort by

Part D drugs prescribed in 2014

Imbruvica	16	$138,639	$8,665
Acyclovir	91	$2,544	$28
Fluconazole	13	$2,134	$164
Tacrolimus	13	$1,746	$134
Fluocinonide	24	$816	$34
Prednisone	37	$473	$13
Pantoprazole	49	$407	$8
Hydrocodone-Acetaminophen	11	$335	$30
Sulfamethoxazole-Trimethoprim	39	$324	$8
Famotidine	11	$72	$7
Lorazepam	14	$72	$5

2013: 17 drugs

Sort by

Part D drugs prescribed in 2013

Gleevec	18	$65,117	$3,618
Voriconazole	14	$24,257	$1,733
Rapamune	11	$7,983	$726
Cyclosporine Modified	11	$2,593	$236
Acyclovir	104	$2,589	$25
Azithromycin	12	$415	$35
Prednisone	45	$333	$7
Pantoprazole	25	$325	$13
Sulfamethoxazole-Trimethoprim	35	$265	$8
Ciprofloxacin	19	$228	$12
Lorazepam	24	$164	$7
Prochlorperazine Maleate	16	$160	$10
Ranitidine	14	$127	$9
Famotidine	12	$123	$10
Zolpidem	13	$92	$7
Amlodipine Besylate	12	$84	$7
Fluoxetine	11	$55	$5

Money from drug and device companies

$11,755 in 2025

Sort by

Industry payments by year

2025	12	41	$7,788	$11,755
2024	9	16	$4,553	$5,466
2023	8	21	None	$17,970
2022	3	11	None	$1,073
2021	3	3	$4,275	$4,300
2020	7	18	$17,175	$18,687
2019	5	32	$27,490	$30,981

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Adaptive Biotechnologies	Clonoseq	$5,039	10 payments Meals for Clonoseq · 2025-12-07 · $36 Meals for Clonoseq · 2025-04-30 · $23 Travel for Clonoseq · 2025-01-23 · $237 Travel for Clonoseq · 2025-01-23 · $152 Travel for Clonoseq · 2025-01-23 · $62 Travel for Clonoseq · 2025-01-23 · $65 Consulting for Clonoseq · 2025-01-23 · $4,400 Meals for Clonoseq · 2025-01-13 · $2 Meals for Clonoseq · 2025-01-13 · $18 Meals for Clonoseq · 2025-01-13 · $44
E.R. Squibb & Sons L.L.C.	None	$2,388	1 payment Consulting · 2025-11-13 · $2,388
Kite Pharma	Yescarta	$2,083	12 payments Meals for Yescarta · 2025-05-21 · $100 Meals for Yescarta · 2025-05-04 · $38 Meals for Yescarta · 2025-05-04 · $53 Meals for Yescarta · 2025-05-04 · $67 Meals for Yescarta · 2025-05-03 · $17 Meals for Yescarta · 2025-05-03 · $28 Meals for Yescarta · 2025-05-03 · $58 Meals for Yescarta · 2025-05-03 · $150 Meals · 2025-05-02 · $99 Meals for Yescarta · 2025-05-02 · $127 Travel for Yescarta · 2025-05-02 · $641 Travel for Yescarta · 2025-05-02 · $707
Eli Lilly and	None	$1,000	1 payment Consulting · 2025-05-12 · $1,000
Gilead Sciences	Yescarta	$507	8 payments Travel for Yescarta · 2025-11-20 · $66 Meals for Yescarta · 2025-11-20 · $125 Meals for Yescarta · 2025-11-20 · $125 Meals for Yescarta · 2025-11-20 · $26 Meals for Yescarta · 2025-11-20 · $16 Meals for Yescarta · 2025-11-20 · $14 Meals for Yescarta · 2025-11-20 · $5 Meals for Yescarta · 2025-10-14 · $130
Celgene	Breyanzi	$223	1 payment Meals for Breyanzi · 2025-05-28 · $223

See all 41 published payments

Sort by

Every published payment

Novartis Pharmaceuticals	Meals · 2025-12-08	Kymriah	$66
Adaptive Biotechnologies	Meals · 2025-12-07	Clonoseq	$36
Gilead Sciences	Travel · 2025-11-20	Yescarta	$66
Gilead Sciences	Meals · 2025-11-20	Yescarta	$125
Gilead Sciences	Meals · 2025-11-20	Yescarta	$125
Gilead Sciences	Meals · 2025-11-20	Yescarta	$26
Gilead Sciences	Meals · 2025-11-20	Yescarta	$16
Gilead Sciences	Meals · 2025-11-20	Yescarta	$14
Gilead Sciences	Meals · 2025-11-20	Yescarta	$5
E.R. Squibb & Sons L.L.C.	Consulting · 2025-11-13	None	$2,388
Gilead Sciences	Meals · 2025-10-14	Yescarta	$130
Celgene	Meals · 2025-05-28	Breyanzi	$223
Kite Pharma	Meals · 2025-05-21	Yescarta	$100
Eli Lilly and	Consulting · 2025-05-12	None	$1,000
BeOne Medicines USA	Meals · 2025-05-08	Brukinsa	$134
Kite Pharma	Meals · 2025-05-04	Yescarta	$38
Kite Pharma	Meals · 2025-05-04	Yescarta	$53
Kite Pharma	Meals · 2025-05-04	Yescarta	$67
Kite Pharma	Meals · 2025-05-03	Yescarta	$17
Kite Pharma	Meals · 2025-05-03	Yescarta	$28
Kite Pharma	Meals · 2025-05-03	Yescarta	$58
Kite Pharma	Meals · 2025-05-03	Yescarta	$150
Kite Pharma	Meals · 2025-05-02	None	$99
Kite Pharma	Meals · 2025-05-02	Yescarta	$127
Kite Pharma	Travel · 2025-05-02	Yescarta	$641
Kite Pharma	Travel · 2025-05-02	Yescarta	$707
Adaptive Biotechnologies	Meals · 2025-04-30	Clonoseq	$23
Janssen Biotech	Meals · 2025-04-05	Carvykti	$79
BeOne Medicines USA	Meals · 2025-04-01	Brukinsa	$48
Novartis Pharmaceuticals	Meals · 2025-02-14	Kymriah	$81
Sobi	Meals · 2025-02-12	Gamifant	$39
Genetix Biotherapeutics	Meals · 2025-02-12	Lyfgenia	$23
Stryker	Meals · 2025-02-05	Ortholoc 3di	$47
Adaptive Biotechnologies	Travel · 2025-01-23	Clonoseq	$237
Adaptive Biotechnologies	Travel · 2025-01-23	Clonoseq	$152
Adaptive Biotechnologies	Travel · 2025-01-23	Clonoseq	$62
Adaptive Biotechnologies	Travel · 2025-01-23	Clonoseq	$65
Adaptive Biotechnologies	Consulting · 2025-01-23	Clonoseq	$4,400
Adaptive Biotechnologies	Meals · 2025-01-13	Clonoseq	$2
Adaptive Biotechnologies	Meals · 2025-01-13	Clonoseq	$18
Adaptive Biotechnologies	Meals · 2025-01-13	Clonoseq	$44

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $5,466

Sort by

Payments by company in 2024

E.R. Squibb & Sons L.L.C.	None	$2,865	1 payment Consulting · 2024-12-13 · $2,865
Novartis Pharma AG	Kymriah	$1,688	1 payment Consulting for Kymriah · 2024-02-28 · $1,688
Gilead Sciences	Yescarta	$277	5 payments Meals · 2024-12-06 · $60 Meals for Yescarta · 2024-06-07 · $25 Meals for Yescarta · 2024-06-07 · $105 Meals for Yescarta · 2024-05-02 · $25 Meals for Yescarta · 2024-05-01 · $63
Kite Pharma	Yescarta	$168	3 payments Meals for Yescarta · 2024-06-11 · $26 Meals · 2024-02-22 · $125 Meals for Yescarta · 2024-02-06 · $17
Sobi	Gamifant	$151	1 payment Meals for Gamifant · 2024-08-27 · $151
Celgene	None	$125	1 payment Meals · 2024-04-03 · $125
Stryker	Citrefix	$98	2 payments Meals for Citrefix · 2024-07-03 · $55 Meals for Sonicanchor · 2024-05-02 · $43
Iovance Biotherapeutics	Amtagvi	$48	1 payment Meals for Amtagvi · 2024-02-23 · $48
Novartis Pharmaceuticals	Kymriah	$47	1 payment Meals for Kymriah · 2024-02-29 · $47

2023: $17,970

Sort by

Payments by company in 2023

Gilead Sciences	Yescarta	$16,567	6 payments Travel for Yescarta · 2023-12-02 · $93 Travel for Yescarta · 2023-11-16 · $254 Travel for Yescarta · 2023-11-02 · $306 Travel · 2023-09-14 · $9,063 Travel · 2023-03-08 · $6,622 Travel · 2023-02-09 · $229
Kite Pharma	Yescarta	$817	7 payments Meals for Yescarta · 2023-12-04 · $22 Travel for Yescarta · 2023-10-05 · $30 Travel for Yescarta · 2023-10-05 · $36 Travel for Yescarta · 2023-09-19 · $237 Travel for Yescarta · 2023-09-19 · $480 Meals for Yescarta · 2023-09-18 · $5 Meals for Yescarta · 2023-09-06 · $6
Novartis Pharmaceuticals	Kymriah	$196	3 payments Meals for Kymriah · 2023-06-21 · $98 Meals for Kymriah · 2023-04-13 · $85 Meals for Kymriah · 2023-02-17 · $13
Novartis Pharma AG	Kymriah	$124	1 payment Meals for Kymriah · 2023-12-10 · $124
AstraZeneca Pharmaceuticals LP	None	$96	1 payment Meals · 2023-07-28 · $96
Adaptive Biotechnologies	Clonoseq	$85	1 payment Meals for Clonoseq · 2023-09-12 · $85
Celgene	None	$48	1 payment Meals · 2023-12-09 · $48
Stryker	Citrefix	$37	1 payment Meals for Citrefix · 2023-11-07 · $37

2022: $1,073

Sort by

Payments by company in 2022

Kite Pharma	Yescarta	$703	6 payments Travel for Yescarta · 2022-12-21 · $342 Meals for Yescarta · 2022-12-11 · $23 Meals for Yescarta · 2022-12-08 · $23 Meals for Yescarta · 2022-12-08 · $115 Meals · 2022-08-11 · $75 Meals · 2022-07-27 · $125
Regeneron Pharmaceuticals	None	$234	4 payments Meals · 2022-12-01 · $39 Meals · 2022-12-01 · $79 Meals · 2022-12-01 · $76 Meals · 2022-12-01 · $40
Adaptive Biotechnologies	None	$136	1 payment Meals · 2022-06-14 · $136

2021: $4,300

Sort by

Payments by company in 2021

Adaptive Biotechnologies	Clonoseq	$2,400	1 payment Consulting for Clonoseq · 2021-12-09 · $2,400
Celgene	None	$1,875	1 payment Consulting · 2021-07-22 · $1,875
CSL Behring	Hizentra	$25	1 payment Meals for Hizentra · 2021-01-15 · $25

2020: $18,687

Sort by

Payments by company in 2020

Kite Pharma	Yescarta	$6,827	10 payments Travel for Yescarta · 2020-02-26 · $35 Meals for Yescarta · 2020-02-26 · $122 Travel for Yescarta · 2020-02-26 · $36 Consulting for Yescarta · 2020-02-12 · $3,990 Travel for Yescarta · 2020-02-03 · $285 Travel for Yescarta · 2020-02-03 · $374 Meals for Yescarta · 2020-01-25 · $32 Travel for Yescarta · 2020-01-25 · $414 Meals for Yescarta · 2020-01-25 · $40 Consulting for Yescarta · 2020-01-08 · $1,500
Celgene	None	$2,766	3 payments Consulting · 2020-03-06 · $2,625 Meals · 2020-02-21 · $118 Meals · 2020-02-21 · $24
Adaptive Biotechnologies	Clonoseq	$2,700	1 payment Consulting for Clonoseq · 2020-12-10 · $2,700
Takeda Pharmaceuticals U.S.A.	None	$2,640	1 payment Consulting · 2020-10-22 · $2,640
Janssen Global Services	Imbruvica	$2,480	1 payment Consulting for Imbruvica · 2020-01-16 · $2,480
Janssen Scientific Affairs	Imbruvica	$1,240	1 payment Consulting for Imbruvica · 2020-08-19 · $1,240
Novartis Pharmaceuticals	Kymriah	$34	1 payment Meals for Kymriah · 2020-02-20 · $34

2019: $30,981

Sort by

Payments by company in 2019

Kite Pharma	Yescarta	$24,384	21 payments Consulting for Yescarta · 2019-12-18 · $5,620 Travel for Yescarta · 2019-12-18 · $35 Travel for Yescarta · 2019-12-18 · $65 Consulting · 2019-12-17 · $5,000 Meals · 2019-12-10 · $50 Meals · 2019-12-10 · $40 Meals · 2019-12-10 · $50 Meals · 2019-12-08 · $26 Meals for Yescarta · 2019-12-08 · $49 Consulting for Yescarta · 2019-12-05 · $5,400 Meals for Yescarta · 2019-11-22 · $38 Meals for Yescarta · 2019-11-22 · $38 Meals for Yescarta · 2019-11-22 · $50 Meals for Yescarta · 2019-11-22 · $47 Travel for Yescarta · 2019-11-22 · $799 Travel for Yescarta · 2019-11-21 · $266 Travel for Yescarta · 2019-11-21 · $289 Consulting for Yescarta · 2019-07-12 · $1,800 Consulting · 2019-05-07 · $2,570 Consulting for Yescarta · 2019-02-27 · $2,100 Meals for Yescarta · 2019-02-20 · $52
EUSA Pharma (US)	Sylvant	$6,205	3 payments Consulting for Sylvant · 2019-05-02 · $5,000 Travel for Sylvant · 2019-05-02 · $1,130 Meals for Sylvant · 2019-02-21 · $74
Novartis Pharmaceuticals	Kymriah	$278	6 payments Meals for Kymriah · 2019-08-20 · $10 Meals for Kymriah · 2019-08-19 · $5 Meals for Kymriah · 2019-08-14 · $10 Meals for Kymriah · 2019-06-04 · $84 Meals for Kymriah · 2019-02-22 · $77 Meals for Kymriah · 2019-01-17 · $93
Adaptive Biotechnologies	Clonoseq	$96	1 payment Meals for Clonoseq · 2019-07-24 · $96
Amgen	Kyprolis	$19	1 payment Meals for Kyprolis · 2019-03-19 · $19

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Adaptive Biotechnologies Corporation · Immunoseq · 2025	Their institution	$1,680,200
Kite Pharma, Inc. · Characterization of Factors Mediating Car T Cell Activation, Expansion, Exhaustion, and Clinical Activity in Patients With Diffuse Large B-Cell Lymphoma (Dlbcl) · 2022	Their institution	$874,067
Kite Pharma, Inc. · Cellular Determinants of Outcomes After Axi-Cel Therapy in Lbcl · 2024	Their institution	$861,407
Kite Pharma, Inc. · Characterization of Factors Mediating Car T Cell Activation, Expansion, Exhaustion, and Clinical Activity in Patients With Diffuse Large B-Cell Lymphoma · 2020	Their institution	$770,033
Kite Pharma, Inc. · Axelerate: Axicabtagene Ciloleucel Efficacy and Patient Outcomes With Rapid Turnaround Manufacturing Process · 2025	Their institution	$657,608
Kite Pharma, Inc. · Cellular Determinants of Outcomes After Axi-Cel Therapy in Lbcl · 2025	Their institution	$504,592
Kite Pharma, Inc. · Blood-Based, Point-of Care Assessment of Car-T Vector Load in Dlbcl Patients Undergoing Axicabtagene Ciloleucel (Axi-Cel) Therapy · 2024	Their institution	$470,000
Kite Pharma, Inc. · A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (Zuma 7) · 2021	Their institution	$409,977
Kite Pharma, Inc. · A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (Zuma 7) · 2019	Their institution	$359,656
Kite Pharma, Inc. · Blood-Based, Point-of-Care Assessment of Car-T Vector Load in Dlbcl Patients Undergoing Axicabtagene Ciloleucel (Axi-Cel) Therapy: A Multi-Site Study · 2022	Their institution	$340,000
Kite Pharma, Inc. · Blood-Based, Point-of-Care Assessment of Car-T Vector Load in Dlbcl Patients Undergoing Axicabtagene Ciloleucel (Axi-Cel) Therapy · 2023	Their institution	$340,000
Kite Pharma, Inc. · A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (Zuma 7) · 2020	Their institution	$307,396
Kite Pharma, Inc. · A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (Zuma 7) · 2022	Their institution	$300,346
Kite Pharma, Inc. · A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (Zuma 7) · 2023	Their institution	$284,062
Regeneron Pharmaceuticals, Inc. · A Phase 1/2 Study of Bbt389, A Dual Targeting Car T Cell Drug Product With Gene Edit in Relapsed and/Or Refractory B-Cell Non-Hodgkin A Lymphoma · 2025	Their institution	$274,339
Adaptive Biotechnologies Corporation · Clonoseq · 2019	Their institution	$168,750
Adaptive Biotechnologies Corporation · Optimizing Ctdna-Based Mrd Assessment in Dlbcl, Mcl, and Fl Patients Undergoing Car Therapy · 2024	Their institution	$168,000
Kite Pharma, Inc. · A Phase 1-2 Study Evaluating the Safety and Efficacy of Kte-C19 in Combination With 4-1bb Dlbcl · 2020	Their institution	$167,040
Gilead Sciences, Inc. · A Phase 1-2 Study Evaluating the Safety and Efficacy of Kte-C19 in Combination With 4-1bb Dlbcl · 2019	Their institution	$107,399
Kite Pharma, Inc. · A Phase 1-2 Study Evaluating the Safety and Efficacy of Kte-C19 in Combination With 4-1bb Dlbcl · 2023	Their institution	$100,796
Kite Pharma, Inc. · A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of Kte-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (Zuma-1) · 2023	Their institution	$88,081
Kite Pharma, Inc. · A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (Zuma 7) · 2025	Their institution	$85,681
Kite Pharma, Inc. · A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of Kte-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (Zuma-1) · 2021	Their institution	$83,747
Adaptive Biotechnologies Corporation · Clonoseq · 2020	Their institution	$82,350
Kite Pharma, Inc. · A Multicenter, Open-Label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-Cell Lymphoma (Zuma 9) · 2023	Their institution	$76,870
Kite Pharma, Inc. · A Multicenter, Open-Label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-Cell Lymphoma (Zuma 9) · 2020	Their institution	$67,789
Kite Pharma, Inc. · A Phase 1-2 Study Evaluating the Safety and Efficacy of Kte-C19 in Combination With 4-1bb Dlbcl · 2021	Their institution	$62,856
Pharmacyclics LLC, an AbbVie Company · Ibrutinib in Combination With Corticosteroids Vs Placebo in Combination With Corticosteroids in Subjects With New Onset Cgvhd · 2022	Their institution	$59,095
Novartis Pharmaceuticals Corporation · A Phase Ib, Multicenter Study To Determine the Safety and Tolerability of Tisagenlecleucel in Combination With Ibrutinib in Adult Patients With Relapsed and/Or Refractory Diffuse Large B-Cell Lymphoma · 2019	Their institution	$55,718
Kite Pharma, Inc. · A Phase 2 Multicenter Study Evaluating the Efficacy of Kte-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (Zuma 2) · 2021	Their institution	$53,492
Pharmacyclics LLC, An AbbVie Company · Pcyc-1140-Im · 2019	Their institution	$51,902
Kite Pharma, Inc. · A Phase 2 Multicenter Study Evaluating the Efficacy of Kte-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (Zuma 2) · 2019	Their institution	$51,896
Kite Pharma, Inc. · A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (Zuma 7) · 2024	Their institution	$51,753
Kite Pharma, Inc. · A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Kte-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Zuma 6) · 2019	Their institution	$40,856
Kite Pharma, Inc. · A Phase 2 Multicenter Study Evaluating the Efficacy of Kte-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (Zuma 2) · 2025	Their institution	$39,844
Pharmacyclics LLC, An AbbVie Company · Pcyc-1140-Im · 2020	Their institution	$39,296
Kite Pharma, Inc. · A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Kte-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Zuma 6) · 2024	Their institution	$38,093
Kite Pharma, Inc. · A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Kte-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Zuma 6) · 2023	Their institution	$37,017
Kite Pharma, Inc. · Blood-Based, Point-of-Care Assessment of Cart Vector Load in Dlbcl Patients(Undergoing Axicabtagene Ciloleucel 9axi-Cel) Therapy · 2024	Their institution	$24,547
Kite Pharma, Inc. · A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Kte-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Zuma 6) · 2020	Their institution	$23,640
Kite Pharma, Inc. · Characterization of Factors Mediating Car T Cell Activation, Expansion, Exhaustion, and Clinical Activity in Patients With Diffuse Large B-Cell Lymphoma (Dlbcl) · 2024	Their institution	$20,000
Regeneron Pharmaceuticals, Inc. · A Phase 1/2 Study of Bbt389, A Dual Targeting Car T Cell Drug Product With Gene Edit in Relapsed and/Or Refractory B-Cell Non-Hodgkin A Lymphoma · 2024	Their institution	$16,654
Kite Pharma, Inc. · A Multicenter, Open-Label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-Cell Lymphoma (Zuma 9) · 2019	Their institution	$15,539
Celgene Corporation · Expanded Access Protocol (Eap) of Subjects Receivi · 2022	Their institution	$14,624
Kite Pharma, Inc. · A Multicenter, Open-Label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-Cell Lymphoma (Zuma 9) · 2024	Their institution	$14,167
Novartis Pharmaceuticals Corporation · A Phase Ib, Multicenter Study To Determine the Safety and Tolerability of Tisagenlecleucel in Combination With Ibrutinib in Adult Patients With Relapsed and/Or Refractory Diffuse Large B-Cell Lymphoma · 2020	Their institution	$13,358
Celgene Corporation · Expanded Access Protocol (Eap) of Subjects Receivi · 2021	Their institution	$10,642
Gilead Sciences, Inc. · A Phase 1-2 Study Evaluating the Safety and Efficacy of Kte-C19 in Combination With 4-1bb Dlbcl · 2020	Their institution	$9,268
Pharmacyclics LLC, an AbbVie Company · Ibrutinib in Combination With Corticosteroids Vs Placebo in Combination With Corticosteroids in Subjects With New Onset Cgvhd · 2021	Their institution	$8,268
Kite Pharma, Inc. · A Phase 1-2 Study Evaluating the Safety and Efficacy of Kte-C19 in Combination With 4-1bb Dlbcl · 2022	Their institution	$4,502
Pharmacyclics LLC, an AbbVie Company · Ibrutinib in Combination With Corticosteroids Vs Placebo in Combination With Corticosteroids in Subjects With New Onset Cgvhd · 2023	Their institution	$3,186
Gilead Sciences, Inc. · A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Kte-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Zuma 6) · 2025	Their institution	$2,752
Kite Pharma, Inc. · A Multicenter, Open-Label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-Cell Lymphoma (Zuma 9) · 2022	Their institution	$2,240
Kite Pharma, Inc. · A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of Kte-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (Zuma-1) · 2022	Their institution	$2,108
Kite Pharma, Inc. · A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of Kte-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (Zuma-1) · 2024	Their institution	$1,633
Kite Pharma, Inc. · A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of Kte-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (Zuma-1) · 2020	Their institution	$1,600
Novartis Pharmaceuticals Corporation · A Phase Ib, Multicenter Study To Determine the Safety and Tolerability of Tisagenlecleucel in Combination With Ibrutinib in Adult Patients With Relapsed and/Or Refractory Diffuse Large B-Cell Lymphoma · 2021	Their institution	$1,250
Pharmacyclics LLC, An AbbVie Company · Pcyc-1129-CA · 2020	Their institution	$866
Adaptive Biotechnologies Corporation · Clonoseq · 2023	Their institution	$600

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1982751053
Licence: CA G87296California G87296: Current · expires 2028-02-29
Trained: Yale University School of Medicine, 1995
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Taxonomy: Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0003X (207RH0003X)
Mailing address: 300 Pasteur Dr, Stanford, CA, 94305
NPI first listed: 2007-01-04
NPI last updated: 2024-04-15
NPI record certified: 2024-04-15

This is when the NPI record was last certified, not a medical board exam.